DOCK4 and breast cancer: The expression of these markers was investigated by immunohistochemistry on primary BC samples belonging to AZURE patients (n = 364 for CAPG and GIPC1; n = 689 for DOCK-4), revealing that subjects whose tumors expressed high levels of both CAPG and GIPC1 significantly benefited from the adjuvant administration of zoledronate in terms of HR reduction for first recurrence in the skeleton (10-fold HR reduction versus placebo, p = 0.008) [86].